Revolutionizing ADC development: The critical role of advanced dispensing systems

In the rapidly evolving landscape of next-generation therapeutics, antibody-drug conjugates (ADCs) have become one of the most powerful classes of targeted cancer treatments. By combining the specificity of monoclonal antibodies with the cytotoxic potency of small molecule drugs, ADCs offer unmatched precision in oncology drug development.

A critical factor in the success of ADC programs is the dispensing system used during development. These advanced platforms play a pivotal role in determining the speed, accuracy, and overall success of ADC development projects.

To explore this further, we spoke with Dr. David McClymont, Head of Automation at Revvity Preclinical Services, about the growing need for innovative dispensing technologies. In our discussion, Dr. McClymont shared expert insights on how automated dispensing systems are reshaping ADC development by accelerating optimization processes and expanding applications into new therapeutic frontiers.

Key topics covered in this interview include:

• Why dispensing systems are essential for successful ADC development
• The most pressing challenges in current dispensing workflows
• How precision dispensing technology will transform next-generation therapeutics
• How the FlexDrop™ dispenser optimizes ADC workflows and accelerates timelines

For research use only. Not for use in diagnostic procedures.